How does recurrent C difficile infection impact health care resources utilization and other medical costs? What are the ways in which recurrent C difficile infection can adversely impact a patient ...

EP: 12.Common Comorbidities Associated With Recurrent C Difficile Infections ...

In vitro, the minimum inhibitory concentration (MIC) values of C. difficile are among the lowest of any enteric pathogen for rifaximin. Gerard et al. [14] identified one study in which 34 of 56 ...

A new study shows that oral fecal microbiota transplantation (FMT) is a feasible and safe addition to preventing graft-versus ...

Intervention models checked against electronic medical record data show ways to help improve infection control practices and reduce infections, according to a recent study.

The use of fecal microbiota, live-jslm (RBL; REBYOTA®) in the prevention of recurrent Clostridioides difficile infection ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

In vitro, nitazoxanide has shown excellent activity against C. difficile. In one study, the 90% MIC (MIC 90) of the toxigenic strains of C. difficile was 0.5 µg/mL for nitazoxanide, which was ...

The pharma company was quick to point out however that the CLOVER trial of PF-06425090 was undermined by a lower-than expected rate of C. diff infection (CDI) as a result of social isolation ...

Biosciences' lead drug candidate, VE303, has been reported to demonstrate efficacy in preventing recurrent Clostridioides difficile infection (rCDI) through multiple mechanisms, according to ...